ArticleColorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland2026
Incidence and outcomes of postoperative paralytic ileus after cytoreductive surgery with HIPEC: A population-based study.
Article in Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Postoperative electrolyte disturbances: Overlooked risk factors for prolonged postoperative ileus after cytoreductive surgery with HIPEC.Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) is standard treatment for peritoneal metastases in Sweden. Prolonged postoperative ileus (PPOI) is a common complication following major abdominal surgery and is associated with increased morbidity and prolonged hospitalization. The aim of this study was to evaluate the incidence of PPOI following CRS-HIPEC and to identify factors associated with its development, including its relationship to postoperative complications.
methodsThis retrospective, bicentre cohort study included patients undergoing CRS-HIPEC for peritoneal metastases between January 2012 and 2024. Patients were identified through the Swedish HIPEC Registry, with supplementary data obtained from medical records. PPOI was defined as delayed defaecation beyond postoperative day 5 and/or prolonged use or reinsertion of a nasogastric tube. Clinical, surgical and postoperative outcomes were analysed and risk factors for PPOI were assessed using a multivariable logistic regression model.
resultsA total of 982 patients were included, of whom 443 (45%) developed PPOI. Patients with PPOI had significantly longer hospital stays (median 11 vs. 9; p < 0.001) and delayed return of bowel function compared with patients without PPOI (median 6 vs. 3 days; p < 0.001). Major complications were more frequently observed in patients with PPOI (36% vs. 16%, p < 0.001). Independent risk factors for PPOI were major postoperative complications (aOR 3.74, CI 2.55-5.48), blood transfusion (aOR 1.70, CI 1.08-2.70) and omentectomy below the gastroepiploic arcade (aOR 1.51, CI 1.01-2.26). This association remained even after excluding patients with major postoperative surgical complications. Ileostomy formation was associated with a reduced risk of PPOI (aOR 0.51, CI 0.33-0.77).
conclusionsPPOI is a frequent complication following CRS-HIPEC and is associated with increased postoperative morbidity and prolonged recovery. Strategies aimed to optimize perioperative care and enhanced recovery protocols may help to reduce the incidence and the adverse effects of PPOI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.